Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Brexpiprazole Intermediates Brexpiprazole CAS 913611-97-9 7-Hydroxyquinolinone CAS 70500-72-0 4-Bromobenzo[b]thiophene CAS 5118-13-8 1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3 7-(4-Chlorobutoxy)quinolin-2(1H)-one CAS 913613-82-8 4-Chlorobenzo[b]thiophene CAS 66490-33-3| Item | Specifications |
| Appearance | Light Yellow Solid Powder |
| Purity / Analysis Method | >97.0% (GC) |
| Infrared Spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Brexpiprazole (CAS: 913611-97-9) |
Description:
Specifications:
Package & Storage:
| Chemical Name | 4-Bromobenzo[b]thiophene |
| Synonyms | 4-Bromobenzothiophene; 4-Bromo-Benzo[b]thiophene; 4-Bromo-1-Benzothiophene |
| CAS Number | 5118-13-8 |
| CAT Number | RF-PI1103 |
| Stock Status | In Stock, Capacity 30MT/Year |
| Molecular Formula | C8H5BrS |
| Molecular Weight | 213.09 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
4-Bromobenzo[b]thiophene (CAS: 5118-13-8) is used as a useful synthetic intermediate, and it is mainly exported to India, North America, Korea, Japanese, and Europe. 4-Bromobenzo[b]thiophene is an intermediate of Brexpiprazole (CAS: 913611-97-9). Brexpiprazole was approved by the U.S. Food and Drug Administration (FDA) on July 10, 2015, for the treatment of schizophrenia, and as an adjunctive treatment for depression. Brexpiprazole has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD). Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic. Brexpiprazole is a dopamine D2 receptor partial agonist and has been described as a "serotonin-dopamine activity modulator" (SDAM). Brexpiprazole was developed by Otsuka and Lundbeck, and is considered to be a successor of Otsuka's top-selling atypical antipsychotic aripiprazole (Abilify).
